Key Highlights

  • Skye Bioscience will merge with Redx Pharma to establish Fibrx Therapeutics, a new Nasdaq-listed entity.
  • The combined company will be dedicated to fibrosis and steered by Redx leadership.
  • The firm will prioritize RXC008, a GI-restricted pan-ROCK inhibitor with Fast Track Designation for fibrostenotic Crohn's disease.
  • The Merger is supported by $125 million in secured funding intended to extend the cash runway into 2029.

Skye Bioscience, Inc. (NASDAQ: SKYE) announced it will merge with Redx Pharma to establish Fibrx Therapeutics, a new Nasdaq-listed entity dedicated to fibrosis and steered by Redx leadership.

What Happened

The combined firm will prioritize RXC008, a GI-restricted pan-ROCK inhibitor with Fast Track designation for fibrostenotic Crohn's disease, supported by $125 million in secured funding intended to extend the cash runway into 2029 and through Phase 2 results anticipated in the second half of 2028.

Market Reaction

The disclosed information does not include stock price or trading data for Skye Bioscience following the merger announcement.

Outlook

Phase 2 results for RXC008 in fibrostenotic Crohn's disease, anticipated in the second half of 2028, represent the next major disclosed milestone for the combined Fibrx Therapeutics entity.